Linda Mileshkin

32.5k total citations · 3 hit papers
273 papers, 6.6k citations indexed

About

Linda Mileshkin is a scholar working on Oncology, Obstetrics and Gynecology and Reproductive Medicine. According to data from OpenAlex, Linda Mileshkin has authored 273 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 160 papers in Oncology, 70 papers in Obstetrics and Gynecology and 51 papers in Reproductive Medicine. Recurrent topics in Linda Mileshkin's work include Endometrial and Cervical Cancer Treatments (70 papers), Ovarian cancer diagnosis and treatment (47 papers) and Cancer Diagnosis and Treatment (32 papers). Linda Mileshkin is often cited by papers focused on Endometrial and Cervical Cancer Treatments (70 papers), Ovarian cancer diagnosis and treatment (47 papers) and Cancer Diagnosis and Treatment (32 papers). Linda Mileshkin collaborates with scholars based in Australia, United States and United Kingdom. Linda Mileshkin's co-authors include Henry C Kitchener, H. Miles Prince, Akila N. Viswanathan, William Small, David K. Gaffney, Linus Chuang, Anuja Jhingran, Monica Bacon, Amishi Bajaj and Brandon J. Fisher and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Linda Mileshkin

261 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cervical cancer: A global health crisis

2017 845 citations Linda Mileshkin et al. profile →
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

2015 341 citations Tjalling Bosse, Remi A. Nout et al. profile →
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

2022 273 citations David M. O’Malley, Antoîne Italiano et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Linda Mileshkin

Since Specialization

Citations

This map shows the geographic impact of Linda Mileshkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Mileshkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Mileshkin more than expected).

Fields of papers citing papers by Linda Mileshkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Mileshkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Mileshkin. The network helps show where Linda Mileshkin may publish in the future.

Co-authorship network of co-authors of Linda Mileshkin

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Mileshkin. A scholar is included among the top collaborators of Linda Mileshkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Mileshkin. Linda Mileshkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor 2025 ·Annals of Oncology ·(unknown), (unknown), John K. Chan, June‐Yong Lee, Mariana Scaranti, (unknown), Carolyn Y. Muller, Linda Mileshkin, Toon Van Gorp, Lyndsay Willmott, Ana Santaballa Bertrán, Elizabeth Munro, (unknown), (unknown), (unknown), Giuseppa Scandurra, Ròbert Póka, (unknown), Birendra Kumar Yadav, (unknown)	0
2	200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study 2024 ·Annals of Oncology ·Tilmann Bochtler, A. Krämer, Chantal Pauli, Gonzalo Durán-Pacheco, Çağatay Arslan, Frédéric Bigot, Nasséra Chalabi, Natalie Cook, Antoîne Italiano, Ferrán Losa, J. Menezes, (unknown), Mustafa Özgüroğlu, (unknown), Jeffrey S. Ross, (unknown), P. Arni, (unknown), Linda Mileshkin	1
3	Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022 2024 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Monique Topp, Linda Mileshkin, Annette M. Lim, James R. Whittle, Stephen J. Luen, Benjamin Solomon, Kurt Lackovic, Jayesh Desai, Ben Tran	0
4	Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Mathias Bressel, (unknown), Yi-An Ko, Anne Hamilton, Clare L. Scott, Linda Mileshkin, (unknown), (unknown), Sumitra Ananda, Jayesh Desai, Danny Rischin, Paul J. Neeson, David D.L. Bowtell, George Au‐Yeung, (unknown)	1
5	Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 2024 ·Journal of Gynecologic Oncology ·Alexander Olawaiye, Jae‐Weon Kim, (unknown), Erin Bishop, Anita Chudecka-Głaz, (unknown), Laurence Gladieff, Mary E. Gordinier, Jacob Korach, Michael McCollum, Linda Mileshkin, Bradley J. Monk, Shibani Nicum, Angélica Nogueira‐Rodrigues, Ana Oaknin, David M. O’Malley, Mauro Orlando, Lyndah Dreiling, Iulia Cristina Tudor, Domenica Lorusso	4
6	A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Sara Bouberhan, Konstantinos Papadimitriou, Rebecca C. Arend, (unknown), Roisin E. O’Cearbhaill, David M. O’Malley, Benoît You, Antonio González-Martı́n, Judith Michels, Linda Mileshkin, Yeh Chen Lee, (unknown), Suk‐Young Yoo, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	7
7	PO003/#269 Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification 2023 ·George Au‐Yeung, Mathias Bressel, Owen W.J. Prall, (unknown), John Andrews, (unknown), Yeh Chen Lee, Bo Gao, Tarek Meniawy, Sally Baron‐Hay, (unknown), Ganessan Kichenadasse, Sumitra Ananda, Peter T. Fox, David D.L. Bowtell, Linda Mileshkin	2
8	PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Félix Blanc‐Durand, (unknown), Etienne Rouleau, Antoine Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, (unknown), (unknown), Natalie Y.L. Ngoi, David S.P. Tan, Alexandra Léary	0
9	819TiP FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours 2023 ·Annals of Oncology ·Funda Meric‐Bernstam, Mi‐Yeon Song, Shannon N. Westin, George Au‐Yeung, Philip B. Mitchell, Chelsea E. Myers, (unknown), (unknown), (unknown), (unknown), Linda Mileshkin	4
10	2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study 2022 ·International Journal of Gynecological Cancer ·Lisa Vermij, Hein Putter, Jan J. Jobsen, Melanie Powell, Stephanie M. de Boer, Alexandra Léary, Paul Bessette, Linda Mileshkin, Ludy Lutgens, Ina M. Jürgenliemk‐Schulz, Annerie Slot, Elzbieta van der Steen-Banasik, Remi A. Nout, Vincent T.H.B.M. Smit, Ewout W. Steyerberg, Carien L. Creutzberg, Tjalling Bosse, Nanda Horeweg	1
11	2022-RA-568-ESGO Prognostic Relevance of FIGO grading is Limited to NSMP Endometrial Cancers 2022 ·International Journal of Gynecological Cancer ·Lisa Vermij, Jan J. Jobsen, Mariël Brinkhuis, (unknown), Alicia León‐Castillo, Naveena Singh, Linda Mileshkin, Melanie Powell, Prafull Ghatage, (unknown), Alexandra Léary, Catherine Genestie, Hans W. Nijman, Ina M. Jürgenliemk‐Schulz, Remi A. Nout, Vincent T.H.B.M. Smit, Stephanie M. de Boer, Carien L. Creutzberg, Nanda Horeweg, Tjalling Bosse	1
12	2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials 2022 ·International Journal of Gynecological Cancer ·(unknown), Stephanie M. de Boer, Melanie Powell, Alexandra Léary, Anthony Fyles, Linda Mileshkin, Naveena Singh, Remi A. Nout, Ina M. Jürgenliemk‐Schulz, Jan J. Jobsen, Ludy Lutgens, (unknown), (unknown), Annerie Slot, Hans W. Nijman, Vincent T.H.B.M. Smit, Tjalling Bosse, Carien L. Creutzberg, Nanda Horeweg	1
13	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards 2021 ·The Medical Journal of Australia ·Eva Segelov, (unknown), Sanchia Aranda, David C. Currow, John Zalcberg, Alexander G. Heriot, Linda Mileshkin, John Coutsouvelis, Jeremy Millar, Brian T. Collopy, Jon Emery, (unknown), (unknown), (unknown), Janet Wale, Stephen Hancock, (unknown), John Bashford	3
14	Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Méder, P.B. Ottevanger, JA Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, (unknown), Ina J. Jürgenliemk-Schulz, H. Kitchener, Hans W. Nijman, Roy F.P.M. Kruitwagen, Vincent T.H.B.M. Smit, Remi A. Nout, Hein Putter, Carien L. Creutzberg	0
15	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer 2018 ·Clinical Cancer Research ·Sarah P. Blagden, Anne Hamilton, Linda Mileshkin, Shirley Wong, Agnieszka Michael, Marcia Hall, Jeffrey C. Goh, Alla Lisyanskaya, Michelle DeSilvio, Eleni Frangou, Euan A. Stronach, Prashanth Gopalakrishna, Tarek Meniawy, Hani Gabra	50
16	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition 2016 ·Clinical Cancer Research ·George Au‐Yeung, (unknown), Walid J. Azar, Thomas J. Mitchell, Kate E. Jarman, Kurt Lackovic, (unknown), Carleen Cullinane, Richard B. Pearson, Linda Mileshkin, Danny Rischin, Alison M. Karst, Ronny Drapkin, Dariush Etemadmoghadam, David D.L. Bowtell	100
17	Acceptability of Early Integration of Palliative Care in Patients with Incurable Lung Cancer 2014 ·Journal of Palliative Medicine ·Brian Le, Linda Mileshkin, (unknown), (unknown), Odette Spruyt, Jaclyn Yoong, Dishan H. Gunawardana, Matthew Conron, Jennifer Philip	46
18	Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1 -Amplified Ovarian Cancer 2013 ·Clinical Cancer Research ·Dariush Etemadmoghadam, George Au‐Yeung, Meaghan Wall, Thomas J. Mitchell, Maya Kansara, Elizabeth Loehrer, (unknown), Joshy George, Sarah Ftouni, Barbara A. Weir, Scott L. Carter, Irma Gresshoff, Linda Mileshkin, Danny Rischin, William C. Hahn, Paul Waring, Gad Getz, Carleen Cullinane, Lynda J. Campbell, David D.L. Bowtell	90
19	Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors 2012 ·Journal of Clinical Oncology ·Jeffrey R. Infante, D. Ross Camidge, Linda Mileshkin, Eric X. Chen, Rodney J. Hicks, Danny Rischin, Howard Fingert, Kristen J. Pierce, Huiping Xu, W. Gregory Roberts, S. Martin Shreeve, Howard A. Burris, Lillian L. Siu	195
20	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib 2011 ·Clinical Cancer Research ·Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact